Pre-clinical proof-of-concept of ALX-0761, a Nanobody® neutralizing both IL-17A and F in a cynomolgus monkey collagen induced arthritis model
用户bdsY2U1qcXNY
2小时前
14
10
求助中
帖子自动结束时间: 2026-03-14 17:13:30
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
K Vanheusden, L Detalle, A Hemeryck…
ARTHRITIS AND …, 2013
academia.edu
Conclusions▪ The preventive effect of ALX-0761 on arthritis development was evaluated by the measurement of arthritis score of the joints, X-ray examination scores of the affected joints, general condition score, C-reactive protein (CRP) concentrations and body weight. In addition, total target levels (both IL-17A and IL-17F) and exploratory pharmaco-dynamic biomarkers (IL-6, IL-15, TNFα and MMP-3) were evaluated.
